wiley

PRESS RELEASE

Wiley Welcomes Ann Begley and Gary Yingling, Expanding the Firm's FDA Regulatory Capabilities

July 27, 2020

Washington, DC – Wiley today announced that leading food and drug lawyers Ann M. Begley and Gary Yingling have joined the firm as partner and senior counsel, respectively, further expanding the firm's U.S. Food and Drug Administration (FDA) regulatory practice and building on the firm's substantial experience in policy, regulatory, and enforcement matters related to the environment and consumer products. In addition, Ms. Begley will serve as chair of Wiley's Food & Drug Practice.

"Ann and Gary have impressive regulatory experience across every sector of FDA-regulated industries," said Peter D. Shields, Wiley's Managing Partner. "The unique combination of their clinical backgrounds and deep legal expertise will provide invaluable insight for our clients. Under Ann's leadership, we will strengthen our ability to meet the increasingly complex needs of the life sciences industry."

"I am honored to join Wiley's team of exceptional attorneys and policy advisors, who make it their mission to stay wired into the ever-changing legal and regulatory landscape our clients must navigate," Ms. Begley said. "With such depth of experience under one roof, Wiley is the right place for highly regulated industries looking for counsel from concept to launch, and through growth and maturity."

"I am also so pleased that Gary Yingling, my colleague and mentor of over 25 years, will be part of this new adventure," Ms. Begley continued. "Gary continues to stay plugged in to all things FDA, and his wise counsel continues to be a hot commodity."

Related Professionals

Ann M. Begley
Partner
202.719.4585
abegley@wiley.law

Practice Areas

Environment & Product Regulation

Food & Drug

Ms. Begley brings extensive experience in FDA and Federal Trade Commission regulatory counseling concerning conventional foods, dietary supplements, drugs, and cosmetic products. She also regularly advises clients on legal and regulatory issues pertaining to industry-sponsored and federally funded clinical research, counseling institutional review boards, clinical investigators, and sponsors on compliance and strategic issues. She provides guidance on product notification and approval pathways, formulation, labeling, and product advertising, and has worked on regulatory aspects of global life sciences transactions. Ms. Begley is a member of the Food and Drug Law Institute, and she is a Board Member on the Inova Health System's Institutional Review Board. She has a J.D., *cum laude*, from Georgetown University Law Center, and a Bachelor of Science in Nursing (B.S.N.) from Georgetown University.

Mr. Yingling advises individuals, partnerships, and corporations on FDA-related matters involving new drug applications, food ingredient marketing, product labeling, importation, regulatory marketing strategy, recalls, and seizures. His practice focuses on such industry issues as clinical research, contract research organization, and sponsor matters. Prior to entering private practice, Mr. Yingling served as president of the Food and Drug Law Institute for nine years. Earlier in his career, he worked in the FDA General Counsel's office, in roles that included trial attorney and deputy chief counsel for administration. Mr. Yingling also was director of the Over-the-Counter Drug Review in the FDA's Bureau of Drugs for two years, for which he received the FDA Award of Merit. He has a J.D. from Emory University School of Law, a Masters from Purdue in Pharmacology, and a B.S. in Pharmacy from the University of North Carolina. Prior to attending law school, he practiced community pharmacy and is a registered pharmacist in Maryland and the District of Columbia.

Wiley's Food & Drug Practice handles complex legal and regulatory challenges, and the more routine but crucial regulatory tasks required of FDA-regulated companies in the pharmaceutical, biotechnology, food, and dietary supplement industries. The practice includes lawyers who have worked at the FDA and as in-house counsel at large consumer product companies – and who have received independent recognition from numerous organizations as leaders in food and drug law.